District court dismisses Teva case against Mylan over four patents on Copaxone

Mylan appeals case involving nine other patents on MS drug

PITTSBURGH — A federal court in New York has dismissed a lawsuit alleging that Mylan infringed four of Teva Pharmaceutical Industries' patents when it sought Food and Drug Administration approval for a multiple sclerosis drug.

Mylan had filed with the FDA for approval of a generic version of Teva's Copaxone (glatiramer acetate), attracting a patent-infringement suit from Teva alleging that it violated four patents on the drug, according to FDA records. The U.S. District Court for the Southern District of New York has dismissed the case.

Mylan said it would appeal to the Federal Circuit a separate decision at the same district court by a different judge that upheld nine other patents.

Are you a nurse practitioner or physician's assistant? Join our Facebook group to get all the latest news dedicated to delivering healthcare services to patients in retail pharmacy clinics.

Poll

Poll

Which of the current U.S. Presidential hopefuls do you think would be best for your business?

Hillary Clinton

Jeb Bush

Donald Trump

Ted Cruz

Ben Carson

Scott Walker

Marco Rubio

Rand Paul

Chris Christie

Mike Huckabee

SPECIAL REPORTS

Pharmacy’s battle for recognition continues

Fifty years ago this summer, President Lyndon B. Johnson secured his place in history by signing into law the legislation that created Medicare and Medicaid. To commemorate the anniversary, Drug Store News has put together an exclusive report on the effect that Medicare and Medicaid have had on the retail pharmacy industry and how it has transformed the role of the pharmacist. more...

IN THIS ISSUE

In this issue, DSN profiles Rite Aid and how the company is achieving a vision to become a retail healthcare company that delivers a higher level of care to its communities; takes you on a tour of Sears; offers insight into millennial shoppers and more. Click here to view the issue.